Description: Veru Inc., a medical therapeutics company, develops, manufactures, and markets consumer health care products. The companys pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus. The company primarily serves global agencies, non-government organizations, ministries of health, and other governmental agencies directly, as well as through distribution agreements and other arrangements with commercial partners. It has operations in the United States, Brazil, Zimbabwe, South Africa, Angola, the Democratic Republic of the Congo, Tanzania, Malaysia, Spain, France, the United Kingdom, and internationally. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Home Page: www.verupharma.com
VERU Technical Analysis
2916 North Miami Avenue
Miami,
FL
33127
United States
Phone:
305 509 6897
Officers
Name | Title |
---|---|
Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D. | Chairman, Pres & CEO |
Dr. Harry Fisch F.A.C.S., M.D. | Vice Chairman & Chief Corp. Officer |
Ms. Michele Greco | CFO & Chief Admin. Officer |
Dr. K. Gary Barnette Ph.D. | Chief Scientific Officer |
Mr. Samuel Fisch | Exec. Director of Investor Relations & Corp. Communications |
Mr. Michael J. Purvis | Exec. VP, Gen. Counsel & Corp. Strategy and Sec. |
Mr. Kevin J. Gilbert CPA, J.D. | Exec. VP of Corp. Devel. |
Dr. Domingo Rodriguez M.D. | Exec. VP of Global Clinical Operations |
Dr. Gary Bird Ph.D. | Exec. VP of Quality & Regulatory Affairs |
Mr. Joel Batten | Exec. VP & GM of Infectious Disease Franchise |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Consumer Staples |
---|---|
GIC Group: | Household & Personal Products |
GIC Industry: | Personal Products |
GIC Sub-Industry: | Personal Products |
Forward PE: | 117.6471 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 5.2161 |
Price-to-Sales TTM: | 10.4686 |
IPO Date: | 1990-07-19 |
Fiscal Year End: | September |
Full Time Employees: | 233 |